Cargando…

Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)

The cytokine storm from the evolution of severe cases of COVID-19, requiring strong immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) infections in these patients. An analysis of the first observational studies in patients with COVID-19 and immunosuppressiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Baroiu, Liliana, Anghel, Lucreția, Laurențiu Tatu, Alin, Iancu, Alina Viorica, Dumitru, Caterina, Leșe, Ana-Cristina, Drăgănescu, Miruna, Năstase, Florentina, Niculeț, Elena, Fotea, Silvia, Nechita, Aurel, Voinescu, Doina Carina, Stefanopol, Anca Ioana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019722/
https://www.ncbi.nlm.nih.gov/pubmed/35495599
http://dx.doi.org/10.3892/etm.2022.11312
_version_ 1784689356747833344
author Baroiu, Liliana
Anghel, Lucreția
Laurențiu Tatu, Alin
Iancu, Alina Viorica
Dumitru, Caterina
Leșe, Ana-Cristina
Drăgănescu, Miruna
Năstase, Florentina
Niculeț, Elena
Fotea, Silvia
Nechita, Aurel
Voinescu, Doina Carina
Stefanopol, Anca Ioana
author_facet Baroiu, Liliana
Anghel, Lucreția
Laurențiu Tatu, Alin
Iancu, Alina Viorica
Dumitru, Caterina
Leșe, Ana-Cristina
Drăgănescu, Miruna
Năstase, Florentina
Niculeț, Elena
Fotea, Silvia
Nechita, Aurel
Voinescu, Doina Carina
Stefanopol, Anca Ioana
author_sort Baroiu, Liliana
collection PubMed
description The cytokine storm from the evolution of severe cases of COVID-19, requiring strong immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) infections in these patients. An analysis of the first observational studies in patients with COVID-19 and immunosuppressive therapy and HBV infection along with special clinical cases was presented, as well as personal experience on a series of cases (a group of 958 patients with COVID-19), compared with the analysis of studies performed on patients with HBV infection that underwent biological therapies for psoriasis and personal experience (a group of 81 psoriasis patients treated with biological therapies). Clinical studies have revealed that HBV reactivation in patients undergoing biological therapies for psoriasis, can be prevented with monitoring and treatment protocols and thus, these therapies have been demonstrated to be safe and effective. In COVID-19, immunosuppressive therapies are short-lived but in high doses, and the conclusions of clinical trials are contradictory, but there are published cases of HBV reactivation, which requires a unitary attitude in the prevention of HBV reactivation in these patients. An algorithm was presented for monitoring and treatment of HBV infection for patients with psoriasis treated with biological therapy and the conditions when this protocol can be used for patients with COVID-19 and immunosuppressive therapy.
format Online
Article
Text
id pubmed-9019722
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-90197222022-04-27 Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review) Baroiu, Liliana Anghel, Lucreția Laurențiu Tatu, Alin Iancu, Alina Viorica Dumitru, Caterina Leșe, Ana-Cristina Drăgănescu, Miruna Năstase, Florentina Niculeț, Elena Fotea, Silvia Nechita, Aurel Voinescu, Doina Carina Stefanopol, Anca Ioana Exp Ther Med Review The cytokine storm from the evolution of severe cases of COVID-19, requiring strong immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) infections in these patients. An analysis of the first observational studies in patients with COVID-19 and immunosuppressive therapy and HBV infection along with special clinical cases was presented, as well as personal experience on a series of cases (a group of 958 patients with COVID-19), compared with the analysis of studies performed on patients with HBV infection that underwent biological therapies for psoriasis and personal experience (a group of 81 psoriasis patients treated with biological therapies). Clinical studies have revealed that HBV reactivation in patients undergoing biological therapies for psoriasis, can be prevented with monitoring and treatment protocols and thus, these therapies have been demonstrated to be safe and effective. In COVID-19, immunosuppressive therapies are short-lived but in high doses, and the conclusions of clinical trials are contradictory, but there are published cases of HBV reactivation, which requires a unitary attitude in the prevention of HBV reactivation in these patients. An algorithm was presented for monitoring and treatment of HBV infection for patients with psoriasis treated with biological therapy and the conditions when this protocol can be used for patients with COVID-19 and immunosuppressive therapy. D.A. Spandidos 2022-06 2022-04-12 /pmc/articles/PMC9019722/ /pubmed/35495599 http://dx.doi.org/10.3892/etm.2022.11312 Text en Copyright: © Baroiu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Baroiu, Liliana
Anghel, Lucreția
Laurențiu Tatu, Alin
Iancu, Alina Viorica
Dumitru, Caterina
Leșe, Ana-Cristina
Drăgănescu, Miruna
Năstase, Florentina
Niculeț, Elena
Fotea, Silvia
Nechita, Aurel
Voinescu, Doina Carina
Stefanopol, Anca Ioana
Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)
title Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)
title_full Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)
title_fullStr Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)
title_full_unstemmed Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)
title_short Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)
title_sort risk of hepatitis b reactivation: from biologic therapies for psoriasis to immunosuppressive therapies for covid-19 (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019722/
https://www.ncbi.nlm.nih.gov/pubmed/35495599
http://dx.doi.org/10.3892/etm.2022.11312
work_keys_str_mv AT baroiuliliana riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT anghellucretia riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT laurentiutatualin riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT iancualinaviorica riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT dumitrucaterina riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT leseanacristina riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT draganescumiruna riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT nastaseflorentina riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT niculetelena riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT foteasilvia riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT nechitaaurel riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT voinescudoinacarina riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review
AT stefanopolancaioana riskofhepatitisbreactivationfrombiologictherapiesforpsoriasistoimmunosuppressivetherapiesforcovid19review